We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, applied for certification of the manufacturing facility in Sawston, UK with the Medicines and Healthcare Products Regulatory ...
Dendritic cell vaccine production capacity for personalized immune therapies increases from about 4 - 6 patients per month to about 40 - 45 patients per month.